SynthesisBMC gastroenterology2020
The effects of resistant starches on inflammatory bowel disease in preclinical and clinical settings: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05138757 (Fiber Supplementation In Children With Peanut Allergy On Oral Immunotherapy), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fiber Supplementation In Children With Peanut Allergy On Oral Immunotherapy: A Randomized Controlled Pilot Study
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- A qualitative evaluation of treatment fidelity alongside a pilot trial of a novel therapy for pediatric Inflammatory Bowel Disease.PloS one · 2024Trial
- Individual variability shapes ex vivo responses to resistant starch in inflammatory bowel disease derived microbiomes.NPJ biofilms and microbiomes · 2026Article
- Pre-Diagnosis Dietary Pattern Differences in Australian Children with Inflammatory Bowel Disease: Exposure Across Ethnicities.Nutrients · 2026Article
- Resistant starch selectively depletes a putative pathobiont-enriched gut microbial module: evidence from multiple dietary fiber intervention cohorts.Frontiers in nutrition · 2026Article
- The capacity of gastrointestinal microbiota in kidney transplant recipients to ferment prebiotic starch.Journal of nephrology · 2025Article
- Review
- Advances in Resistant Starch Research from Agro-Industrial Waste: A Bibliometric Analysis of Scientific Trends.Foods (Basel, Switzerland) · 2025Review
- Resistant Starch and Microbiota-Derived Secondary Metabolites: A Focus on Postbiotic Pathways in Gut Health and Irritable Bowel Syndrome.International journal of molecular sciences · 2025Review
- Impact of Dietary Fiber on Inflammation in Humans.International journal of molecular sciences · 2025Review
- The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases.International journal of molecular sciences · 2024Review
- The Consumption of the Fibrous Fraction ofFoods (Basel, Switzerland) · 2024Article
- Resistant Starch from Purple Sweet Potatoes Alleviates Dextran Sulfate Sodium-Induced Colitis through Modulating the Homeostasis of the Gut Microbiota.Foods (Basel, Switzerland) · 2024Article
- Effects of Consuming Heat-Treated Dodamssal Brown Rice Containing Resistant Starch on Glucose Metabolism in Humans.Nutrients · 2023Article
- To Fiber or Not to Fiber: The Swinging Pendulum of Fiber Supplementation in Patients with Inflammatory Bowel Disease.Nutrients · 2023Review
- Review
- Increasing the Versatility of Durum Wheat through Modifications of Protein and Starch Composition and Grain Hardness.Foods (Basel, Switzerland) · 2022Review
- Lactulose Modulates the Structure of Gut Microbiota and Alleviates Colitis-Associated Tumorigenesis.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is a debilitating chronic disease with limited treatment options. Resistant starches may represent a novel treatment for IBD. However, its efficacy and safety remain unclear. Our objective was to perform a systematic review to summarize the preclinical and clinical effects of resistant starch, which may help guide future studies.
methodsMedline, EMBASE, and the Cochrane Central Register were searched. Included studies investigated the use of resistant starch therapy in in vivo animal models of IBD or human patients with IBD. Articles were screened, and data extracted, independently and in duplicate. The primary outcomes were clinical remission (clinical) and bowel mucosal damage (preclinical).
results21 preclinical (n = 989 animals) and seven clinical (n = 164 patients) studies met eligibility. Preclinically, resistant starch was associated with a significant reduction in bowel mucosal damage compared to placebo (standardized mean difference - 1.83, 95% CI - 2.45 to - 1.20). Clinically, five studies reported data on clinical remission but clinical and methodological heterogeneity precluded pooling. In all five, a positive effect was seen in patients who consumed resistant starch supplemented diets. The majority of studies in both the preclinical and clinical settings were at a high or unclear risk of bias due to poor methodological reporting.
conclusionsOur review demonstrates that resistant starch is associated with reduced histology damage in animal studies, and improvements in clinical remission in IBD patients. These results need to be tempered by the risk of bias of included studies. Rigorously designed preclinical and clinical studies are warranted. Trial registration The review protocols were registered on PROSPERO (preclinical: CRD42019130896; clinical: CRD42019129513).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.